[Federal Register Volume 79, Number 8 (Monday, January 13, 2014)]
[Notices]
[Page 2157]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-00285]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Notice of Availability for Exclusive, Non-Exclusive, or 
Partially-Exclusive Licensing of an Invention Concerning Contact 
Pathway and Tissue Kallikrein Inhibitors Can Prevent/Reduce Leakage 
Caused by Hantavirus

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Provisional Patent Application Serial No. 
61/851,573, entitled ``Contact Pathway and Tissue Kallikrein Inhibitors 
can Prevent/Reduce Leakage Caused by Hantavirus,'' filed on March 15, 
2013. The United States Government, as represented by the Secretary of 
the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to treatment of 
vascular leakage symptoms infected with the Hantavirus using drugs that 
are already FDA approved.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2014-00285 Filed 1-10-14; 8:45 am]
BILLING CODE 3710-08-P